| Budget Amount *help |
¥22,620,000 (Direct Cost: ¥17,400,000、Indirect Cost: ¥5,220,000)
Fiscal Year 2014: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2013: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2012: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
|
|---|
| Outline of Final Research Achievements |
We focused on microRNA (miR) and histone methylation. Serum expression level of miR-1246 was significantly higher and it showed usefulness as a new biomarker in esophageal cancer patients. MiR-1246 was secreted from cancer cells by exosome and could participates in cancer progression. We confirmed that miR-375 which expression was attenuated in esophageal cancer tissues by miR expression profiling had a strong antitumor effect, and it could become a new treatment tool. It was shown that histone modification participated in expression of miR-375. NCL1 which was histone demethylase inhibitor had a strong antitumor effect, and it could be a new molecular target agent.
|
